Home > News > PSivida losses almost all due to R&D
August 30th, 2004
PSivida losses almost all due to R&D
pSivida Limited (PSD) today reported that after deducting outside equity interest they had recorded a loss attributable to the members of pSivida of $3.6 million for financial year ending 30 June 2004, compared to a loss of $2.7 million in 2003. The consolidated entity of the global nanotechnology company incurred a net loss of $7.5 million, compared to $5.3 million in 2003. The operating loss includes $7,million in research and development costs expended by pSiMedica and administrative expenses totalling $888,961.
Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015
Aspen Aerogels, Inc. Schedules Fourth Quarter and Fiscal 2014 Earnings Release and Conference Call for February 26, 2015 February 11th, 2015
Arrowhead to Report Fiscal 2015 First Quarter Financial Results February 2nd, 2015
Graphenea sales more than double in 2014 January 29th, 2015